Recent News for BHVN - Biohaven Pharmaceutical Holding Company Ltd.

Date Title
Mar 22 The Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback
Mar 21 Sell-siders say Biogen may seek acquisitions after aducanumab fail
Mar 18 Biohaven to raise $200M to fund priority review voucher buy
Mar 18 GW Pharma sells Priority Review Voucher for $105M
Mar 18 Biohaven Secures Priority Review Voucher (PRV) To Expedite Regulatory Review Of Rimegepant Zydis ODT New Drug Application
Mar 14 Biohaven Pharmaceutical Holding Co Ltd (BHVN) CEO Vlad Coric Sold $5 million of Shares
Mar 14 Has Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Got Enough Cash?
Mar 14 Late-stage study of Biohaven's troriluzole in rare neurodegenerative disorder underway
Mar 14 Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole
Mar 13 Biohaven nearing the finish line with migraine med Zydis
Mar 13 Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant
Mar 6 The Daily Biotech Pulse: Horizon Pharma Under DoJ Radar, FDA Greenlights J&J's Depression Drug, Endologix Reverse Split
Mar 5 Factors of Influence in 2019, Key Indicators and Opportunity within Expedia Group, Lumentum, Patterson Companies, Allscripts Healthcare Solutions, AtriCure, and Biohaven Pharmaceutical Holding — New Research Emphasizes Economic Growth
Feb 28 Biohaven Pharmaceuticals reports Q4 results
Feb 28 Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial And Recent Business Results
Feb 28 The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems
Feb 27 Biohaven's Trigriluzole: A Contender In The Race To Treat Alzheimer's Disease?
Feb 26 The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote
Feb 21 What Makes Biohaven Pharmaceutical Holding Company Ltd. (BHVN) a Strong Momentum Stock: Buy Now?
Feb 20 Biohaven enrolls first patient in Phase 3 GAD trial of troriluzole
Feb 20 Biohaven Enrolls First Patient In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
Feb 19 FDA grants Biohaven's verdiperstat ODD for MSA
Feb 19 Biohaven's Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy
Feb 15 Biohaven's verdiperstat designated orphan drug
Feb 4 Biohaven advances migraine candidate BHV-3500

Back to the Main BHVN Page...